Abstract
Histone proteins are subject to a diverse range of post-translational modifications which, along with DNA methylation, play a major role in controlling gene expression, cell division, survival and differentiation. Alterations in these chromatin modifications are thought to contribute to important human diseases including cancer. Inhibition of the enzymes that introduce and remove these chromatin modifications is proving an effective approach to cancer therapy and inhibitors of histone deacetylases and DNA methyltransferases have been approved for use in haematological malignancies. Here we provide a background to the biology of chromatin modifications and review some of the evidence validating histone deacetylases and DNA methyltransferases as targets for anti-cancer drug discovery. We then focus on two of the key issues in this field; the identification of novel inhibitors to overcome shortcomings of first generation agents and the potential role of histone deacetylase and DNA methyltransferase inhibitors in combination therapies for oncology. Finally, we highlight some of the challenges that will need to addressed to further progress the development of epigenetic-based therapies for cancer.
Keywords: Epigenetic, chromatin, histone, DNA methylation, acetylation, histone deacetylase, inhibitor
Current Cancer Drug Targets
Title: Epigenetic Therapy: Histone Acetylation, DNA Methylation and Anti-Cancer Drug Discovery
Volume: 9 Issue: 8
Author(s): A. Ganesan, L. Nolan, S. J. Crabb and G. Packham
Affiliation:
Keywords: Epigenetic, chromatin, histone, DNA methylation, acetylation, histone deacetylase, inhibitor
Abstract: Histone proteins are subject to a diverse range of post-translational modifications which, along with DNA methylation, play a major role in controlling gene expression, cell division, survival and differentiation. Alterations in these chromatin modifications are thought to contribute to important human diseases including cancer. Inhibition of the enzymes that introduce and remove these chromatin modifications is proving an effective approach to cancer therapy and inhibitors of histone deacetylases and DNA methyltransferases have been approved for use in haematological malignancies. Here we provide a background to the biology of chromatin modifications and review some of the evidence validating histone deacetylases and DNA methyltransferases as targets for anti-cancer drug discovery. We then focus on two of the key issues in this field; the identification of novel inhibitors to overcome shortcomings of first generation agents and the potential role of histone deacetylase and DNA methyltransferase inhibitors in combination therapies for oncology. Finally, we highlight some of the challenges that will need to addressed to further progress the development of epigenetic-based therapies for cancer.
Export Options
About this article
Cite this article as:
Ganesan A., Nolan L., Crabb J. S. and Packham G., Epigenetic Therapy: Histone Acetylation, DNA Methylation and Anti-Cancer Drug Discovery, Current Cancer Drug Targets 2009; 9 (8) . https://dx.doi.org/10.2174/156800909790192428
DOI https://dx.doi.org/10.2174/156800909790192428 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Relevance of Vitamin D in Bone and Muscle Health of Cancer Patients
Anti-Cancer Agents in Medicinal Chemistry Resveratrol Targets in Inflammation
Endocrine, Metabolic & Immune Disorders - Drug Targets Editorial: Lipoprotein (a), More than Just Cholesterol?
Current Medicinal Chemistry Bioinformatics Approaches to Profile the Tumor Microenvironment for Immunotherapeutic Discovery
Current Pharmaceutical Design Pore-Forming Proteins and their Application in Biotechnology
Current Pharmaceutical Biotechnology Discrimination of Thermophilic and Mesophilic Proteins Using Support Vector Machine and Decision Tree
Current Proteomics MicroRNAs in Glioblastoma: Role in Pathogenesis and Opportunities for Targeted Therapies
CNS & Neurological Disorders - Drug Targets Microsomal Prostaglandin E Synthase: A Key Enzyme in PGE2 Biosynthesis and Inflammation
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents The Design of Clinical Trials for New Molecularly Targeted Compounds: Progress and New Initiatives
Current Pharmaceutical Design Expression of Specificity Protein Transcription Factors in Pancreatic Cancer and their Association in Prognosis and Therapy
Current Medicinal Chemistry Survivin: Role in Normal Cells and in Pathological Conditions
Current Cancer Drug Targets Role of Protein Tyrosine Phosphatases in Plants
Current Genomics Synthesis of Cyclodextrin-based Adsorbents and its Application for Organic Pollutant Removal from Water
Current Organic Chemistry Adeno-Associated Virus (AAV) Vectors in the CNS
Current Gene Therapy Editorial [Hot Topic: Nanomedicine and Drug Delivery (Executive Editors: A.V. Kabanov and K. Levon)]
Current Pharmaceutical Design Cancer Stem Cell as a Potential Therapeutic Target in Hepatocellular Carcinoma
Current Cancer Drug Targets Drug Delivery Systems for the Treatment of Diabetes Mellitus: State of the Art
Current Pharmaceutical Design New Perspectives in Glioblastoma: Nanoparticles-based Approaches
Current Cancer Drug Targets Choosing between Targeted Therapies for Rheumatoid Arthritis Patients: The Oncology Perspective
Current Rheumatology Reviews Plasma Proteins Interaction with Curcumin Nanoparticles: Implications in Cancer Therapeutics
Current Drug Metabolism